Anavex Life Sciences Corp.
$0.59-$0.08 (-11.4%)
Last close · Data as of Nov 20, 2026
- Market cap
- $261.3M
- P/E
- -5.6x
- Revenue
- $0.00
- ROCE
- -54.1%
Price chart
Technical chartScreen technicals →-81.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -56.5%
- 3M
- -81.1%
- 6M
- -78.5%
- 1Y
- -81.3%
- 5Y
- -97.1%
52-week range
Day change -$0.08 (-11.4%) from $0.67 to $0.59 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in AVXL, bought on each weekday since 2021.
News & filings
What Anavex Life Sciences filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 46.4 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are more than ten times current liabilities.
- Revenue is too small for margins and growth rates to be read, so those points are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer .
Read moreShow less
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
- Sector
- Healthcare
- Shares outstanding
- 86.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $261.3M
- P/E
- -5.6x
- P/B
- 2.8x
- 52-week high
- $5.30
- 52-week low
- $0.59
Profitability
- ROE
- -48.9%
- ROCE
- -54.1%
- ROA
- -44.7%
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $0.00
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 7.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$39.0M
Solvency
- Current ratio
- 11.60
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- CFO / Net profit
- 0.84
- Cash / Market cap
- 39.3%
Revenue and net profit
Annual revenue, with net profit as the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$48.0M |
| FY2023 | $0.00 | -$47.5M |
| FY2024 | $0.00 | -$43.0M |
| FY2025 | $0.00 | -$46.4M |
Cash flows
FY2025: -$39.0M from operations, -$39.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$24.2M | -$24.2M |
| FY2023 | -$27.8M | -$27.8M |
| FY2024 | -$30.8M | -$30.8M |
| FY2025 | -$39.0M | -$39.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $0.00
- EBITDA
- -$46.4M
- Net profit
- -$46.4M
- Cash from operations
- -$39.0M
- Free cash flow
- -$39.0M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $0.00 | -$46.4M | -$46.4M | -$39.0M | -48.9% | — | +7.8% |
Monthly returns
Month-by-month returns of AVXL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $103.8M |
| Current assets | $103.8M |
| Non-current assets | $0.00 |
| Liabilities | $8.9M |
| Current liabilities | $8.9M |
| Non-current liabilities | $0.00 |
| Equity | $94.9M |
| Paid-in capital | $477.2M |
| Retained earnings | -$382.4M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; AVXL highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Anavex Life Sciences Corp., Eledon Pharmaceuticals, Inc., Nuvectis Pharma, Inc., Protara Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Anavex Life Sciences Corp.AVXLthis company | $261.3M | -5.6x | 2.8x | -48.9% | — |
| Eledon Pharmaceuticals, Inc.ELDN | $277.9M | -6.1x | 3.4x | -56.3% | -3.1x |
| Entrada Therapeutics, Inc.TRDA | $271.7M | -1.9x | 0.9x | -47.0% | -1.5x |
| Akebia Therapeutics, Inc.AKBA | $260.3M | -48.7x | 8.0x | -16.4% | 5.9x |
| Fate Therapeutics, Inc.FATE | $257.6M | -1.9x | 1.2x | -65.8% | -2.1x |
| Nuvectis Pharma, Inc.NVCT | $256.5M | -9.7x | 13.9x | -143.6% | — |
| Codexis, Inc.CDXS | $254.5M | -5.8x | 5.0x | -87.0% | -8.2x |
| Sight Sciences, Inc.SGHT | $250.3M | -6.5x | 3.9x | -60.1% | -6.1x |
| Protara Therapeutics, Inc.TARA | $247.9M | -4.3x | 1.3x | -29.2% | -3.1x |
| Peer median | — | -5.9x | 3.7x | -58.2% | -3.1x |
Year-to-date ROI
AVXL since 1 January, against earlier years.
Historical volatility
AVXL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $0.00 |
| Operating expensesOperating Expense | $51.4M |
| Research and developmentResearch And Development | $37.6M |
| Selling, general and administrativeSelling General And Administration | $13.8M |
| Other operating expensesOther Operating Expenses | -$40.0k |
| Total expensesTotal Expenses | $51.4M |
| Operating incomeOperating Income | -$51.4M |
| Interest and other | |
| Pretax incomePretax Income | -$46.4M |
| TaxTax Provision | — |
| Net incomeNet Income | -$46.4M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $103.8M |
| Current assetsCurrent Assets | $103.8M |
| Non-current assetsTotal Non Current Assets | $0.00 |
| LiabilitiesTotal Liabilities Net Minority Interest | $8.9M |
| Current liabilitiesCurrent Liabilities | $8.9M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $0.00 |
| EquityTotal Equity Gross Minority Interest | $94.9M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$39.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$39.0M |
| Net income, continuing operationsNet Income From Continuing Operations | -$46.4M |
| Stock-based compensationStock Based Compensation | $11.6M |
| Change in working capitalChange In Working Capital | -$4.2M |
| Other non-cash itemsOther Non Cash Items | — |
| Financing cash flowFinancing Cash Flow | $9.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $9.4M |
| Shares issuedIssuance Of Capital Stock | $9.2M |
| Common stock issuedCommon Stock Issuance | $9.2M |
| Net common stock issuedNet Common Stock Issuance | $9.2M |
| Stock options exercisedProceeds From Stock Option Exercised | $2.9M |
| Other financing chargesNet Other Financing Charges | — |
| Change in cashChanges In Cash | -$29.6M |
| Cash at the start of the yearBeginning Cash Position | $132.2M |
| Cash at the end of the yearEnd Cash Position | $102.6M |
| Free cash flowFree Cash Flow | -$39.0M |
| Supplemental |
Learn while you research
Academy chapters picked for Anavex Life Sciences Corp. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read